TBC
TBC
Validation Strategies for Pharmaceutical Patents in Europe
Special Report
The decision on where to validate a pharmaceutical European patent is a big one. With costs often precluding an “everywhere” approach for small- to medium-sized companies, research institutions and universities, it is necessary to choose from the long list of available countries. The choice typically factors in costs, business interests, likely markets and market size, possible manufacturing and import locations and the regulatory framework in Europe.
This report explores these choices and factors using publicly available data, seeking to answer questions such as:
- Which countries are most commonly picked by patent holders at the EPO?
- Is the distribution the same for pharmaceutical patents?
- Where does “big pharma” choose to validate?
- What factors might affect the choice of countries?
Read our blogs
UPC Weekly - Who counts as an infringer? Court of Appeal clarifies director liability
2025 Week 41 The UPC Court of Appeal’s second ruling on the merits is out in the Philips v. Belkin case. This decision broadens who can be considered an “infringer” beyond those directly performing ...
.png)
Five Under Discussed Trends in ADC Innovation
What came up when we asked the experts: what's next for antibody-drug conjugates?
Mewburn Ellis Congratulates Prof. Shimon Sakaguchi on Nobel Prize for Treg Cell Discovery
We are thrilled that Dr Shimon Sakaguchi, distinguished Professor at Osaka University’s Immunology Frontier Research Center, is one of the winners of the Nobel Prize in Physiology or Medicine for the ...
UPC Weekly - UPC Court of Appeal overturns first instance to tighten up on added matter
2025 Week 40 The UPC Court of Appeal (CoA) has no problem making up its own mind about the substance of cases before it. We have seen various reversals of first instance preliminary injunction ...
Celebrating Women: A Toast to Connection
We were thrilled to host the first event in our new Celebrating Women series at our London office at 8 Bishopsgate, an evening designed to bring together women working across life sciences to ...
UPC Weekly - Apple-scuse me? Intervening to protect confidential information
2025 Week 39 New orders from the UPC Court of Appeal (CoA) this week bring together two running strands of case law at the UPC – the rules about confidentiality clubs and the hurdle for third parties ...
Mewburn Ellis
FORWARD MAGAZINE
Mewburn Ellis Forward is a biannual publication that celebrates the best of innovation and exploration. Through its pages we hope to inform and entertain, but also to encourage discussion about the most compelling developments taking place in the scientific and entrepreneurial world. Along the way, we’ll engage with the IP challenges that international organisations face every day.